Cargando…
Screening of Botanical Drugs against SARS-CoV-2 Entry Reveals Novel Therapeutic Agents to Treat COVID-19
An escalating pandemic caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) has severely impacted global health. There is a severe lack of specific treatment options for diseases caused by SARS-CoV-2. In this study, we used a pseudotype virus (pv) containing the SARS-CoV-...
Autores principales: | Cao, Junyuan, Liu, Yang, Zhou, Minmin, Dong, Siqi, Hou, Yuxia, Jia, Xiaoying, Lan, Xiaohao, Zhang, Yueli, Guo, Jiao, Xiao, Gengfu, Wang, Wei |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2022
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8877376/ https://www.ncbi.nlm.nih.gov/pubmed/35215943 http://dx.doi.org/10.3390/v14020353 |
Ejemplares similares
-
Screening of Botanical Drugs against Lassa Virus Entry
por: Liu, Yang, et al.
Publicado: (2021) -
Screening and Identification of Lujo Virus Entry Inhibitors From an Food and Drug Administration-Approved Drugs Library
por: Cao, Junyuan, et al.
Publicado: (2021) -
Screening and Identification of Lassa Virus Entry Inhibitors from a Fragment-Based Drug Discovery Library
por: Hou, Yuxia, et al.
Publicado: (2022) -
RNA Interference Screening Reveals Requirement for Platelet-Derived Growth Factor Receptor Beta in Japanese Encephalitis Virus Infection
por: Zhou, Minmin, et al.
Publicado: (2021) -
Bergamottin, a bioactive component of bergamot, inhibits SARS-CoV-2 infection in golden Syrian hamsters
por: Zhou, Minmin, et al.
Publicado: (2022)